Effect of transfusion convalescent recovery plasma in patients with coronavirus disease 2019.
10.11817/j.issn.1672-7347.2020.200318
- Author:
Kun XIAO
1
;
Yang LIN
2
;
Zhifang FAN
3
;
Yuchuan WEN
4
;
Huiqing HUANG
5
;
Min WANG
6
;
Dequan REN
6
;
Chenggao WU
7
;
Wei LIU
7
;
Zhanglin ZHANG
7
;
Guoliang LI
7
;
Aiping LE
8
Author Information
1. Department of Blood Transfusion, First Affiliated Hospital of Nanchang University, Nanchang 330006. 376069793@qq.com.
2. Department of Respiration, First Affiliated Hospital of Nanchang University, Nanchang 330006.
3. Fuzhou Central Blood Station, Fuzhou Jiangxi 344000.
4. Yichun Central Blood Station, Yichun Jiangxi 336000.
5. Jiangxi Province Blood Center, Nanchang 330052.
6. Shicheng Shangsheng Single Plasma Collection Ltd, Ganzhou Jiangxi 342700, China.
7. Department of Blood Transfusion, First Affiliated Hospital of Nanchang University, Nanchang 330006.
8. Department of Blood Transfusion, First Affiliated Hospital of Nanchang University, Nanchang 330006. leaiping@126.com.
- Publication Type:Journal Article
- Keywords:
convalescent recovery plasma;
coronavirus disease 2019;
severe acute respiratory syndrome coronavirus 2
- MeSH:
Betacoronavirus;
Blood Component Transfusion;
China;
Coronavirus Infections;
therapy;
Humans;
Immunization, Passive;
Pandemics;
Plasma;
Pneumonia, Viral;
therapy;
Retrospective Studies
- From:
Journal of Central South University(Medical Sciences)
2020;45(5):565-570
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To evaluate curative effects of coronavirus disease 2019 (COVID-19) patients by the transfusion of other convalescent plasma.
METHODS:Retrospective analysis of the clinical data of 18 patients with severe and critical COVID-19, who were hospitalized in the ICU of Xianghu Branch of the First Affiliated Hospital of Nanchang University from February 1 to March 15, 2020. Patients were subdivided into an experimental group (=6, who had transfused the plasma) and an observation group (=12, who had no plasma transfusion). Basic clinical data and prognosis indexes of these two groups were compared. Moreover, for the experimental group, the dynamic changes of blood oxygen saturation before and after the transfusion, the changes of lymphocyte absolute value 48 hours after the transfusion, and the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid were analyzed.
RESULTS:There were no significant differences in age, gender, blood type and other basic clinical data between the two groups (all >0.05).There were no significant differences in ventilator machine weaning time, extracorporeal membrane oxygenation (ECMO) weaning time, body temperature recovery to normal time, and hospitalization days between these two groups (all >0.05). For the experimental group, before, during and after the convalescent plasma transfusion, the blood oxygen saturation of all 6 patients at all time (1, 6, 8, 12, 24, 36, and 48 h) was more than 90%, and there was no significant fluctuation. There were 3 patients whose absolute value of lymphocyte was increased 48 hours after the transfusion, and the remaining was decreased. There were 5 patients whose SARS-CoV-2 nucleic acid detection turned negative 48 hours after the transfusion, accounting for 83.3%.
CONCLUSIONS:Transfusion of convalescent plasma will not affect outcomesof COVID-19 patients, which can neutralize SARS-CoV-2 in patients and reduce the loading capacity of SARS-CoV-2.
